Skip to main content

Advertisement

Table 2 Summary of MET status and sensitivity to ABT-700 in a panel of 35 human cancer lines

From: Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification

Cell line Type Source FISH WB Proliferation  
    MET (mean/cell) CEP7 (mean/cell) Ratio MET/CEP7 Total c-Meta Phospho-(Y1234) c-Meta Max Inhibition by (%)
         PF-4217903b ABT-700c
SNU620 gastric KCLB 41.6 4.4 10.6 6.7 56 95 80
H1993 lung ATCC 32 11.9 2.8 5.4 829 50 30
Hs746T gastric ATCC 22.2 3.9 6.6 6 377 55 40
OE33 esophageal Sigma 21.4 6.9 3.1 6 430 60 70
SNU5 gastric ATCC 20.2 7.9 2.6 12 910 95 90
EBC1 lung JCRB 15.6 3.1 5.2 6 374 85 30
MKN45 gastric JCRB 12.6 3.4 4 10 297 96 50
H1573 lung ATCC 11.5 4.3 2.7 1.8 5 0 0
H2342 lung ATCC 8.6 5.2 1.7 0.7 1.3 0 0
H820 lung ATCC 8.3 5 1.7 2.9 5.7 20 0
NUGC-2 gastric JCRB 7.8 8.2 1 0.5 0.1 0 0
FU97 gastric JCRB 7.6 7.5 1 0.1 0.1 0 0
NUGC-4 gastric JCRB 6 5.1 1.3 1 15 50 0
SNU-16 gastric ATCC 5.1 5.7 0.9 0.5 2.5 0 0
KATOIII gastric ATCC 4.6 5 0.9 0.9 16 0 0
SNU-216 gastric KCLB 4.5 4.7 1 0.8 0.5 0 0
MKN-1 gastric JCRB 4.4 3.8 1.2 0.2 0.1 0 0
SNU-484 gastric KCLB 4.2 4 1 0.1 0.1 0 0
SNU-668 gastric KCLB 3.6 3.6 1 1.9 0.5 0 0
SNU-1 gastric ATCC 3.3 3.2 1 NA NA 0 0
RERF-GC-1B gastric JCRB 3.1 4.2 0.8 0.6 0.6 0 0
OCUM-1 gastric JCRB 3 2.9 1 0.4 0.3 0 0
SCH gastric JCRB 3 3.5 0.9 0.3 0 0 0
NCC-StC-K140 gastric JCRB 2.8 9 0.3 0.5 0.3 30 0
SNU-719 gastric KCLB 2.7 3.5 0.8 0.4 0.1 0 0
IM95 gastric JCRB 2.5 2.5 1.1 0.2 0.5 90 60
MKN74 gastric JCRB 2.4 2.6 1 0.1 0.1 0 0
SNU-601 gastric KCLB 2.4 3 0.8 0.4 2.6 0 0
U87MG glioblastoma ATCC 2.1 2.1 1 0.5 3 30 30
23132/87 gastric DSMZ 2 1.9 1.2 0.5 0.2 0 0
AGS gastric ATCC 2 2.2 1 0.2 0.1 0 0
NUGC-3 gastric JCRB 2 3.2 0.7 0.5 1.1 0 0
SNU638 gastric KCLB 2 2 1 3.6 28 80 50
TAKIGAW gastric JCRB 2 5.1 0.4 0.4 0.1 0 0
NCI-N87 gastric ATCC 1 2 0.5 NA NA 0 0
A549 lung ATCC NA NA NA 1 1 0 0
  1. aNormalized to actin and relative A549 which was assigned 1
  2. bat 1 μM concentration that is known to fully inhibit cellular c-Met with minimal off-target effect [21, 28]
  3. cat 10 μg/mL (~67 nM) that saturates c-Met binding